👤 Daiyue Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaocun Li, Jianyu Li, Xinzhi Li, Guanqiao Li, Zequn Li, Guang-Xi Li, Yubo Li, Bugao Li, Qingchao Li, Xikun Li, Hong-Tao Li, Guobin Li, Xihao Li, Rongqing Li, Chang-Da Li, Meng-Yue Li, DaZhuang Li, Shunqin Li, Jiajie Li, Yaqiong Li, Yuan-hao Li, Yongmei Li, X Y Li, Peilin Li, Ran Li, Chunshan Li, Yixiang Li, Guanglve Li, Ye Li, Zili Li, Yihao Li, Qing Run Li, Liling Li, Meng-Yang Li, Ziyun Li, Jun-Ying Li, Xinhai Li, Yongjiang Li, Wanru Li, Wenhao Li, Shisheng Li, Sai Li, Guangwen Li, Hua Li, Dongmei Li, Jiayang Li, Zunjiang Li, Minglong Li, Wenzhe Li, Zihan Li, Jin-Long Li, Hongxin Li, Caiyu Li, Fa-Hui Li, Guangpu Li, Teng Li, Wen-Jie Li, Hegen Li, Ang Li, Zhizong Li, Lu-Yun Li, Peng Li, Shiyu Li, Fang Li, Jiuke Li, Miyang Li, Mingxu Li, Chen-Xi Li, Panlong Li, Changwei Li, Biyu Li, Yaoqi Li, San-Feng Li, Jiaming Li, Jiyuan Li, Rongkai Li, Yani Li, Linke Li, C Y Li, Thomas Li, Siting Li, Yongnan Li, Jinchen Li, Jin-Ping Li, Xuewen Li, R Li, Xianlong Li, Aixin Li, Xuening Li, Guang Li, Xiaoming Li, Z-H Li, Yongli Li, Baohong Li, Shuyuan Li, L Li, Yuanmei Li, Yanwu Li, Hualing Li, Sibing Li, Xining Li, Qinghe Li, Zonghua Li, Liqin Li, Jingya Li, Youjun Li, Zheng-Dao Li, Zhenshu Li, Heng-Zhen Li, Yuhui Li, Wen-Ying Li, Wei Li, Shuanglong Li, Fei-feng Li, Letai Li, Kangli Li, Ming Li, Wenbo Li, Runwen Li, Yarong Li, Weidong Li, S E Li, Xin-Tao Li, Ruotong Li, Shuguang Li, Xiuzhen Li, Lingxi Li, Chuan-Hai Li, Tingting Li, Guanghua Li, Zhongyu Li, Zhen-Yu Li, Deyu Li, Hansen Li, Jinzhi Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Qintong Li, Naishi Li, Xin-Ping Li, Han-Ni Li, Jiaying Li, Cui-lan Li, Ruonan Li, Jun-Jie Li, Shuhao Li, Ruitong Li, Suyan Li, Gen-Lin Li, Dianjie Li, Junhui Li, Ya-Jun Li, Xue Cheng Li, Ding-Biao Li, Xiying Li, Yansong Li, Weiyong Li, Xinyang Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Wenxue Li, Jianglin Li, Yingpu Li, Yan-Hua Li, Jing-Yao Li, Shawn Shun-Cheng Li, Xiao-Min Li, Wan Jie Li, Ya-Ting Li, Dongbiao Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Chunyi Li, Peiyun Li, Qinglan Li, Yue-Ting Li, Da Li, YiPing Li, Demin Li, Haipeng Li, Chuan Li, Ze-An Li, Jianmin Li, Minhui Li, Yu Li, Yiwei Li, Xiangzhe Li, Minglun Li, Xue-Min Li, Kenneth Kai Wang Li, Chunlan Li, Chiyang Li, Hulun Li, Juan-Juan Li, Hua-Zhong Li, Jiaomei Li, Xiangyun Li, Jing Li, Yingshuo Li, Baixing Li, Dengke Li, Qingling Li, Rui-Han Li, Dong Li, Xiaoxia Li, Dezhi Li, Sheng-Jie Li, Ying-Qing Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Sha-Sha Li, Mengxuan Li, Ziyu Li, Gang Li, Panyuan Li, Hong-Wen Li, Xiaojuan Li, Dongnan Li, Huaiyuan Li, Ji-Liang Li, Huaping Li, C H Li, Bohua Li, Pei-Ying Li, Shaobin Li, Ronald Li, Shilun Li, Shi-Hong Li, John Zhong Li, Xinyu Li, Lujiao Li, Song-Chao Li, Chenghong Li, Baohua Li, Nianfu Li, Jun-Cheng Li, Yimeng Li, Chunting Li, Chien-Feng Li, Mei-Zhen Li, Zhengjie Li, Liwei Li, Yan-Yan Li, Huijun Li, Chengyun Li, Lijun Li, Hening Li, Fengxia Li, Jialing Li, Xin Li, Ningyan Li, Zhenghui Li, Ailing Li, Chaochen Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Wenjing Li, Jingshu Li, Han-Bo Li, Zengyang Li, Chunyan Li, Runzhen Li, Xi-Hai Li, Xuezhong Li, MengGe Li, Pei-Lin Li, Wan-Xin Li, Ruobing Li, Ning Li, Meitao Li, Xia Li, Ziqiang Li, Wen-Xi Li, Shenghao Li, Hehua Li, Yucheng Li, Dujuan Li, Yuying Li, Shaofei Li, Shaoguang Li, Min-Rui Li, Shuqiang Li, Dan C Li, Huashun Li, Ganggang Li, Haoqi Li, Handong Li, Yan-Nan Li, Xianglong Li, Jing-Jing Li, Songhan Li, Conglin Li, Qingli Li, Miao Li, Chenyu Li, Ke Li, Zhen-Hua Li, Chuan-Yun Li, Gaoyuan Li, Youming Li, Qingrun Li, Dong-Yun Li, Shuangfei Li, Fengfeng Li, Qinggang Li, Huixia Li, Xingye Li, Xiangjun Li, Huiying Li, Xingyu Li, Zhaoping Li, Wenying Li, Honghui Li, Cheung Li, Xuelian Li, Zhenming Li, Changyan Li, Mulin Jun Li, Shangjia Li, Jingjing Li, Suhong Li, Xinping Li, Siyu Li, Guangzhen Li, Xiangyan Li, Shiyun Li, Xiaoyu Li, Yaobo Li, Xuewang Li, Mei Li, Manjiang Li, Wan Li, Xiao-Li Li, Xiaoya Li, Shan Li, Shitao Li, Zehan Li, Lijia Li, Huiliang Li, Chunqiong Li, Junjun Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Wenxi Li, Chang-hai Li, Yuqiu Li, Xue-Yan Li, Yuan-Yuan Li, Xiang-Jun Li, Chia Li, Y X Li, Yunyun Li, Zhen-Jia Li, Qiuxuan Li, De-Jun Li, Keqing Li, Junxian Li, Shuwen Li, Lingjun Li, Deheng Li, Si-Xing Li, Yaodong Li, Shigang Li, Gao-Fei Li, Minle Li, Le-Le Li, Ziwen Li, Yongqiu Li, Pu-Yu Li, Nan-Nan Li, Lan-Lan Li, Hongming Li, Shuang Li, Wanting Li, Gong-Hua Li, Zhengyu Li, Weiguang Li, Guoqing Li, Xiaomeng Li, Yuanze Li, Yunqi Li, Yuandong Li, Changcheng Li, Shiyue Li, Hanbo Li, Yinggao Li, Dingshan Li, Linlin Li, Jin-Wei Li, Cheng-Tian Li, Yaxi Li, Wei-Ming Li, Ming-Han Li, Wenchao Li, Guangyan Li, Zhaosha Li, Xuesong Li, Chun-Quan Li, Yongzhen Li, Tao Li, Xiankai Li, Yaxuan Li, Tian-wang Li, Yuchan Li, Jiaxi Li, Yalin Li, Pei-Zhi Li, Guanyu Li, Jinlan Li, Huizi Li, Jianping Li, Yun-Lin Li, Yadong Li, Sujing Li, Wenzhuo Li, Xuri Li, Mengqiu Li, Yun Li, Ling-Ling Li, Chengwen Li, Shu-Feng Li, Haojing Li, Zhiyu Li, Ziyang Li, Yaochen Li, Qian Li, Bohao Li, Wenyang Li, Wenming Li, Mingxuan Li, Bingsong Li, Anqi Li, Shuai Li, Xiaoju Li, Na Li, Huibo Li, Chuanfang Li, Pengsong Li, Ruotian Li, Chunya Li, En-Min Li, Zong-Xue Li, Yan Ning Li, Honglin Li, Min-jun Li, Jinhua Li, Qian-Qian Li, Yuanheng Li, Chunxiao Li, Shijun Li, Kuan Li, Baoguang Li, Jie-Shou Li, Zimeng Li, Mengmeng Li, W-B Li, Binkui Li, Yu-Sheng Li, Junjie Li, Xiaoqi Li, Xiucui Li, Haihua Li, Yu-Lin Li, Tsai-Kun Li, Shujing Li, Mengyun Li, Mingna Li, Lanlan Li, Moyi Li, Xiyun Li, Ya-Pei Li, Zhongjie Li, Zhenbei Li, Shuangshuang Li, Hongwei Li, Ding-Jian Li, Xiao-Qiang Li, Danni Li, Min Li, Pengyang Li, Kun-Xin Li, Xiangpan Li, Zesong Li, Mingfei Li, Shuwei Li, Mingdan Li, Xihe Li, Jianfeng Li, Dexiong Li, Rongsong Li, Yinxiong Li, Hong-Yu Li, Weijian Li, Changhui Li, Dechao Li, Wenxia Li, Guoxiang Li, Ziru Li, Juxue Li, Man Li, Huayin Li, Xiao-yu Li, Jianyi Li, Guowei Li, Xingya Li, Gongda Li, Yajun Li, Wei-Ping Li, Nanjun Li, P H Li, Ranran Li, Suping Li, Jason Li, Monica M Li, Xianlun Li, Qi Li, Xiaoli Li, Xionghui Li, Fei Li, Hongmei Li, Xu-Wei Li, Mengsen Li, Quanpeng Li, Yajiao Li, Qilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Cheng-Lin Li, Yousheng Li, Wen-Ting Li, Guoping Li, A Li, Simin Li, Weiguo Li, Xue-Nan Li, Xiaoying Li, Shengsheng Li, Hong Li, Yuqi Li, Zihua Li, Qing Li, Jiaping Li, Weiyang Li, Feng Li, Peihong Li, Jin-Mei Li, Lisha Li, Cuicui Li, Kaibo Li, Hanbing Li, Meng-Hua Li, J T Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Donghe Li, Zheng Li, Congfa Li, Wenrui Li, Yong Li, Xiuling Li, Jingqi Li, Zhiyong Li, Xiao-Kang Li, Hanqi Li, Yangyang Li, Dongfang Li, Zhuorong Li, X-H Li, Dong Sheng Li, Lan-Juan Li, Xianrui Li, Zhigao Li, Chenlin Li, Zihui Li, Guoli Li, Huanqiu Li, Zhan Li, Weisong Li, Xinglong Li, Xiaozhen Li, Zhiyang Li, Cunxi Li, Ying Li, Jianlin Li, Yanshu Li, Guiying Li, Jinku Li, Cuiling Li, Zhisheng Li, Changgui Li, Xuekun Li, Yuguang Li, Wenke Li, Jiayi Li, Suwen Li, Peihua Li, Chang-Ping Li, Guangda Li, Jieming Li, Chunhui Li, Tongyao Li, Peiyu Li, Linfeng Li, Yuzhe Li, Qifang Li, Chang-Yan Li, Xiaolin Li, Duanxiang Li, Vivian Li, Justin Li, Meiting Li, Xue-Er Li, Hongchang Li, Youwei Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Xinmin Li, Luquan Li, Guoxing Li, Jianyong Li, Zongchao Li, Jia Li, Haimin Li, Sheng-Qing Li, Lingjie Li, Yiwen Li, Baoqi Li, Leyao Li, Xiao-Qin Li, Jiajing Li, Yanlin Li, Liao-Yuan Li, Yongkai Li, Hangwen Li, Hengguo Li, An-Qi Li, Xuehua Li, AnHai Li, Chenli Li, Zhengrui Li, Rumei Li, Yan-Yu Li, Lipeng Li, Qinqin Li, Qinghua Li, Leilei Li, Lianyong Li, Zhou Li, Q Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Jian'an Li, Guangqiang Li, Sichong Li, Wenyi Li, Qing-Min Li, Meiyan Li, Yun-Da Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Shen Li, Ziqi Li, Yunfeng Li, Shufen Li, Yueqi Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Pinghua Li, Xu Li, Zhenli Li, Yunxiao Li, Rosa J W Li, Hsin-Yun Li, XiaoQiu Li, Zhankui Li, Zhi Li, Zhijie Li, Huimin Li, Ruifang Li, Xiao-xu Li, Man-Xiang Li, Cong Li, Chengbin Li, Yuping Li, G Li, Zhi-Yong Li, Yukun Li, Xiong Bing Li, Wen Lan Li, Qingjie Li, Han Li, Yutang Li, Hankun Li, Hongling Li, Zhifan Li, Yan-Guang Li, Ji-Min Li, Peipei Li, Tian-Yi Li, Zhihao Li, Yao Li, Zheyun Li, Zhonglin Li, Lin Li, Jinfang Li, Chenjie Li, Yanming Li, S L Li, Ben-Shang Li, Hong-Lan Li, Xionghao Li, Shunqing Li, Ming-Kai Li, Lan Li, Yanwei Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Yong-Liang Li, M Li, Jiehan Li, Hongguo Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Ai-Qin Li, Zichao Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Yanjiao Li, Jia-Huan Li, Guoxi Li, Xudong Li, Xingfang Li, Jisheng Li, Rongyao Li, Ru Li, Jiangya Li, Yiche Li, Yilang Li, Yunshen Li, Jingchun Li, Hexin Li, H J Li, Yanping Li, Qing-Wei Li, Qiang Li, Hsiao-Hui Li, L I Li, Hongzheng Li, Laiqing Li, Ningyang Li, Zhongxia Li, Guangquan Li, Shun Li, Hui-Jun Li, Xuefei Li, Guojun Li, Hung Li, Senlin Li, Jinping Li, Sainan Li, Jinghui Li, Zulong Li, Chengsi Li, P Li, Fulun Li, Yonghao Li, Mingli Li, Yehong Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Gan Li, Shichao Li, Dapei Li, Zejian Li, Lihong Li, Haixia Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Zhao Li, Kui Li, Yunxu Li, Xuanfei Li, Zilin Li, Mingqiang Li, Xiaojiao Li, Yinzhen Li, Yunsheng Li, Li-Min Li, Xiangqi Li, Jia-Peng Li, Wenqi Li, Haibo Li, Xiao-Jun Li, Yan-Hong Li, Shi Li, Xueling Li, Conghui Li, Xiaoxiong Li, Wanni Li, Chitao Li, Haiyang Li, Xiaobai Li, Pingping Li, Mingquan Li, Suran Li, Yuanfang Li, Yingqin Li, Qiner Li, Jiafang Li, Shanhang Li, Han-Bing Li, Zongzhe Li, Yikang Li, Si-Yuan Li, Hongmin Li, Caihong Li, Yajing Li, Benyi Li, Yuquan Li, Hongzhi Li, Chengxin Li, Xiaojiaoyang Li, Xinxin Li, Jian-Shuang Li, Yubin Li, Dazhi Li, Chenglan Li, Yuhong Li, Fengqiao Li, Di Li, Yanbing Li, Jufang Li, Zecai Li, Qipei Li, Xiaoning Li, Xiyue Li, Minghua Li, Tianchang Li, Zhuoran Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Yi-Ling Li, Yingjian Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Cai Li, Jingcheng Li, Ivan Li, Mengshi Li, Manxia Li, Ya Li, Dan-Ni Li, Wen-Chao Li, Sunan Li, Zhencong Li, Lai K Li, Jiong Li, Bingong Li, Chunxue Li, Yunlong Li, Jianshuang Li, Juanling Li, Xinbin Li, Xue-jing Li, Yuling Li, Yetian Li, Xianlin Li, Chuangpeng Li, Mingrui Li, Yanjun Li, Jiequn Li, Zhongding Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xinyan Li, Xiaoyun Li, Yushan Li, Ping'an Li, Weiping Li, Huan Li, Changjiang Li, Chengping Li, He-Zhen Li, G-P Li, Yinliang Li, Wen Li, Weihai Li, Yu-Kun Li, Jiangan Li, Zhaojin Li, Bingxin Li, Wenjuan Li, Chia-Yang Li, Wenyu Li, Hairong Li, Su Li, Mei-Lan Li, Wenjun Li, Jiaxin Li, Chenguang Li, Ming D Li, Ruyue Li, Xiaolian Li, Ya-Ge Li, Yinyan Li, Guangli Li, Rujia Li, Qijun Li, Lixia Li, Yunrui Li, Yuhuang Li, Shanshan Li, Wan-Shan Li, Jing-gao Li, Yiyang Li, Fengxiang Li, Nana Li, Jingui Li, Huamao Li, Xiankun Li, Jingke Li, Tianyao Li, Xiaowei Li, Junming Li, Hai-Yun Li, Zhongxian Li, H-J Li, Zhixiong Li, Lingyan Li, Xuhang Li, Chen-Lu Li, Jialun Li, Xinjian Li, Zilu Li, Sheng-Fu Li, Zezhi Li, Xue-Fei Li, Yudong Li, Hongjiang Li, Jingyun Li, Binghua Li, Hanjun Li, Qihua Li, Jin-Qiu Li, Jiaxuan Li, Guangjin Li, Xutong Li, Ranwei Li, Kai Li, Wei-Li Li, Keanning Li, Ling Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Baoguo Li, Jianrong Li, Zhehui Li, Chenghao Li, Weike Li, Chuanbao Li, Zhixuan Li, Chuzhong Li, M D Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Ling-Zhi Li, Hengtong Li, Yifan Li, Ya-Li Li, Songyun Li, Xiaoran Li, Bolun Li, Linchuan Li, Jiachen Li, Haibin Li, Huangbao Li, Guo-Chun Li, Xinli Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Xinrui Li, Hanbin Li, Wanwan Li, Jia Li Li, Wan-Hong Li, Mingke Li, Huanhuan Li, Xiaoyuan Li, Zongfang Li, Yang Li, BoWen Li, Duoyun Li, Yimei Li, Zhi-qiang Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Zhiping Li, Yan-Li Li, Haiming Li, Gaijie Li, Yuemei Li, Xuefeng Li, Xiao-Hong Li, Mengjuan Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Yi Li, Baosheng Li, Mian Li, Yujun Li, Lixi Li, Jin-Xiu Li, Jiwen Li, Zhouhua Li, Qingqin S Li, Honglei Li, Guojin Li, Xin-Yue Li, Dingchen Li, Xiaoling Li, Meng-Jun Li, Peining Li, Congjiao Li, Huilin Li, Songtao Li, Fusheng Li, Dai Li, Meiyue Li, Kechun Li, Keshen Li, Yuxin Li, Shaoliang Li, Shu-Xin Li, Hong-Zheng Li, Tianye Li, Qun Li, Zhen Li, Mengling Li, Jia-Da Li, Baoqing Li, Pu Li, Xingli Li, Bingkun Li, Nien-Chi Li, Tiewei Li, Daniel Tian Li, Rong-Bing Li, Wei-Yang Li, Rong Li, Mingkun Li, Binxing Li, Zixiao Li, Guixin Li, Quanzhang Li, Da-wei Li, Xiumei Li, Melody M H Li, Peibo Li, Huanjun Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Tianyou Li, Jipeng Li, Longxuan Li, Shi-Guang Li, Wenxiu Li, Zhuang Li, Yu-Hao Li, Shilin Li, Shili Li, Meiqing Li, Hengyu Li, Yinhao Li, Junying Li, Mufan Li, Chun-Lai Li, Shiya Li, Xiao-Jiao Li, Li Li, Hanxue Li, Lulu Li, L P Li, Xiaoqin Li, Chunmei Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Ji-Cheng Li, Haolong Li, Xuanzheng Li, Peng-li Li, Quan Li, Xue-Ying Li, Yongzhe Li, Tianyi Li, Qingfeng Li, Nanlong Li, Ping Li, Fangzhou Li, Nien-Chen Li, Yuanchuang Li, Haiying Li, Yunting Li, Hong-Yan Li, Shengbiao Li, Yue-Rui Li, Ruidong Li, Y M Li, Sijie Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Qiuyan Li, Tingguang Li, Xiangyang Li, Chunjie Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jie-Pin Li, Kaiyi Li, Junyi Li, Dongtao Li, Fengyuan Li, Chenxi Li, Zuo-Lin Li, Zhengwei Li, Yan-Chun Li, Suiyan Li, Qiaoqiao Li, Xiaotian Li, Zhenguang Li, Jia-Ru Li, Pei-Qin Li, Chun-Xiao Li, Shu-Hong Li, Shuyue Li, Quan-Zhong Li, Tongzheng Li, Fangyan Li, Duo Li, Ren Li, Hongye Li, Lanfang Li, Mingwei Li, Wenxin Li, W J Li, Zhijia Li, Jingtong Li, Lucy Li, Zhengpeng Li, Xiayu Li, Baolin Li, Cuilan Li, Yuting Li, Xiaobo Li, Meijia Li, Shujiao Li, Kun-Ping Li, Weirong Li, Weihua Li, Runzhao Li, Xiang-Dong Li, Yanxin Li, Xiufeng Li, Yingjun Li, Xiaohuan Li, Ying-Qin Li, Fan Li, Jun Z Li, Yiheng Li, Taiwen Li, Xiaorong Li, Haifeng Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Rui-Jún Eveline Li, Xuanxuan Li, Bing-Mei Li, Yunman Li, Shuhua Li, Chunying Li, Leipeng Li, Weiheng Li, Baizhou Li, Han-Ru Li, Sheng Li, Yaqiang Li, Guoyin Li, Qiwei Li, Chengjun Li, Jianxiong Li, Ji Li, Huaying Li, Tuojian Li, Yixin Li, Ziyue Li, Juntong Li, Xiang Li, Chaonan Li, Yu-Chia Li, Heying Li, Shaomin Li, Yuxuan Li, Xuan-Ling Li, Bingshan Li, Jiahao Li, Shibao Li, Ruijin Li, Kunlong Li, Xiaofeng Li, Zhaolun Li, Litao Li, Ruyi Li, Wanxin Li, Jinsong Li, Ying-Lan Li, Yulin Li, Shaojian Li, Mohan Li, Yan-Xue Li, Enhong Li, Xiangnan Li, Yong-Jun Li, Hang Li, Ziming Li, Jing-Ming Li, Yuanchang Li, Xiao-Lin Li, Yicun Li, Zhao-Yang Li, K-L Li, Xinjia Li, Bin Li, Jianhai Li, Peiwu Li, Youran Li, Changyu Li, Ming Zhou Li, Z Li, Xinmei Li, Wulan Li, Haoxian Li, Xiaozhao Li, Da-Lei Li, Jinming Li, Huihui Li, Kailong Li, Qiankun Li, Shengxu Li, Xiuli Li, Yulong Li, Ru-Hao Li, Zhi-Peng Li, Lanzhou Li, Tingsong Li, Binjun Li, Chen Li, Yawei Li, Chao Bo Li, Donghua Li, Siming Li, Fengli Li, Song Li, Hsin-Hua Li, You Li, Dongfeng Li, Zhen-Yuan Li, Xuelin Li, Xueyang Li, Bao Li, Yin Li, Cai-Hong Li, Dejun Li, Yufeng Li, Miaoxin Li, Hu Li, Bei Li, W H Li, Sha Li, Ya-Qiang Li, Xiushen Li, Jinlin Li, Xiaoqing Li, Shuaicheng Li, Xuebiao Li, Yingyi Li, Maolin Li, Jiyang Li, Zhongxuan Li, Linting Li, Zhong-Xin Li, Enhao Li, Shengliang Li, Hujie Li, Yue-Ming Li, Zhaohan Li, Alexander Li, Wen-juan Li, Pilong Li, Yun-Peng Li, C X Li, Huanan Li, Miao X Li, KeZhong Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yaokun Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Side Li, Timmy Li, Jiezhen Li, Qiuya Li, Haitao Li, Yufen Li, Qin Li, Annie Li, Wenge Li, Xueren Li, Chun-Mei Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Junping Li, Xiao Li, PeiQi Li, Xiaobing Li, Liangdong Li, Yan Li, Shengchao A Li, Pan Li, Huiqiong Li, Guigang Li, Lucia M Li, Chunzhu Li, Chengquan Li, Zexu Li, Zhilei Li, Tiantian Li, Wenyong Li, Desen Li, Tianjun Li, Zihao Li, Fadi Li, Huawei Li, Yu-quan Li, Jihua Li, Jingping Li, Zhiquan Li, Zeyu Li, Zongdi Li, Ming V Li, Aowen Li, L K Li, Aimin Li, Tiehua Li, Guohong Li, Botao Li, L-Y Li, Xiuqi Li, Zhenhua Li, Zhengda Li, Haotong Li, Luhan Li, Yuancong Li, Tian Li, Yuxiu Li, Beibei Li, Changhong Li, Yvonne Li, Zhichao Li, Jiayuan Li, Yige Li, Siguang Li, Chengqian Li, Weiye Li, Dong-fei Li, Xiangchun Li, Hailong Li, Kun-Peng Li, Haijun Li, Si Li, Ji-Feng Li, Wanqian Li, Zijing Li, Wentao Li, Yuchuan Li, Xuhong Li, Hongyun Li, Zhonggen Li, Xiong Li, Penghui Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Defa Li, X L Li, Yuyan Li, Kawah Li, Shupeng Li, Zhenfei Li, Zhuo Li, Han-Wei Li, Weina Li, Xiao-Hui Li, Rui-Fang Li, Jianzhong Li, Bing Li, Huihuang Li, Yunmin Li, Yanying Li, Gui Lin Li, Chenrui Li, Dengfeng Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Zhimei Li, Jiao Li, Jingming Li, Jinxia Li, De-Tao Li, Shu Li, Julia Li, Huilan Li, Xin-Ya Li, Chunsheng Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Supeng Li, Yiju Li, Yuanhe Li, Guangxiao Li, Xueqin Li, Peixin Li, Feng-Feng Li, Zu-Ling Li, Yunjiu Li, Dayong Li, Zonghong Li, Lingjiang Li, Yuhan Li, Fuyuan Li, H-F Li, Chunxia Li, Zhen-Li Li, Zhengying Li, Zhaoshui Li, Yali Li, Yu-Hui Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Stephen Li, Shuangding Li, Mangmang Li, Kaiyuan Li, Xiaopeng Li, Anan Li, Luying Li, Jiajv Li, Xiaoquan Li, Yanxi Li, Yongjing Li, Huayao Li, Jiqing Li, Huixue Li, Boxuan Li, Yongqi Li, Qingyuan Li, Fengqi Li, Yuqing Li, Zhigang Li, Guiyang Li, Guo-Qiang Li, Yanbo Li, Sanqiang Li, Hongyu Li, Guangping Li, Jinxin Li, Xinrong Li, Yayu Li, Huaixing Li, Minyue Li, Hong-Mei Li, Jutang Li, Mengxia Li, Yongxiang Li, Qilong Li, Songlin Li, Dijie Li, Yizhe Li, Yan Bing Li, Jiani Li, Lianjian Li, Yiliang Li, Xinpeng Li, Hongxing Li, Wanyi Li, Mi Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Yumiao Li, Jiexi Li, Kecheng Li, Junxu Li, Junya Li, Jiang Li, Shengxian Li, Qingyang Li, Yuxi Li, Chenxuan Li, Xiao-Dong Li, Xinghuan Li, Zhenlu Li, Xiaolei Li, Huilong Li, Xiao-Gang Li, Zhenhui Li, Chunjun Li, Shu-Fen Li, Yinghua Li, Yanjie Li, Chaoying Li, Juanjuan Li, Qiu Li, Kunlun Li, Shiquan Li, Xiangdong Li, Zhenjia Li, Jifang Li, Zhizhong Li, Ding Yang Li, Chenlong Li, Shujin Li, Weining Li, Wu-Jun Li, Yumao Li, Bin-Kui Li, Honglian Li, Ya-Zhou Li, Hongyi Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Man-Zhi Li, Xiancheng Li, Yanmei Li, Zhihua Li, Minqi Li, Saijuan Li, Danxi Li, Mimi Li, Yingjie Li, Yuan-Hai Li, Lujie Li, Minghao Li, Meifen Li, Yifeng Li, Huanqing Li, Yuhang Li, Jianhua Li, Chanjuan Li, Lingyi Li, Yanchuan Li, Bai-Qiang Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Mingyao Li, Ze Li, R H L Li, Guisen Li, Dongyang Li, Jinglin Li, Honglong Li, Mingfang Li, Hanmei Li, Chenmeng Li, Shiyang Li, Jianing Li, Xinsheng Li, Jin-Jiang Li, Zhi-Xing Li, Chang Li, Jiwei Li, Weifeng Li, Wenhui Li, Sichen Li, Qingsheng Li, Liangji Li, Lixiang Li, Jin-Liang Li, Xiaoqiong Li, You Ran Li, Yixiao Li, Kathy H Li, Yuhua Li, Deqiang Li, Y Li, Mingyue Li, Zipeng Li, Caixia Li, Hongli Li, Yanfeng Li, Yaqin Li, Yu-He Li, Shasha Li, S-C Li, Xi Li, Siyi Li, Minmin Li, Manna Li, Dawei Li, Xun Li, Ming-Jiang Li, Sitao Li, Tinghua Li, Zhenfen Li, Shuo Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Xiaonan Li, Zhenyu Li, Ting Li, Xiang-Yu Li, Duan Li, Lei Li, Hongde Li, Fengqing Li, Yanchang Li, Xunjia Li, Ruixia Li, Nanzhen Li, Hongxue Li, Bingjie Li, Xiaojing Li, Xinlin Li, Yu-Ying Li, Wenli Li, Mengze Li, Kaiwei Li, Huangyuan Li, Lili Li, Junxin Li, Wei-Jun Li, Guoyan Li, Fei-Lin Li, Nuomin Li, Yanyan Li, Shulin Li, Shanglai Li, Taibo Li, Yue Li, Junqin Li, JunBo Li, Jun-Ru Li, Xueying Li, Zhongcai Li, Zhaobing Li, Linxin Li, Jen-Ming Li, Chen-Chen Li, Hongquan Li, Chuan F Li, Yanxiang Li, Yi-Wen Li, Shihong Li, Rulin Li, Huifeng Li, Lijuan Li, Yuanhong Li, Shengbin Li, Jingyu Li, Xuewei Li, Long Li, Min-Dian Li, Wenjia Li, Xiatian Li, Yangxue Li, Chengnan Li, Chuanyin Li, Yiqiang Li, Zhenzhou Li, Xiawei Li, Binglan Li, Yutong Li, Yingnan Li, Ge Li, Xinzhong Li, Chenyao Li, Jun-Yan Li, Boru Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Chuanning Li, Jiafei Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Chunxing Li, Qiao-Xin Li, Huang Li, Shu-Fang Li, Qiusheng Li, Weiqin Li, Xinming Li, Yongjun Li, Mengyang Li, Guo-Jian Li, Chenglong Li, Nan Li, Yipeng Li, Mingxing Li, Xin-Yu Li, Chunyu Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Long Shan Li, Yanze Li, Xiao-Feng Li, W Li, Fengjuan Li, Hainan Li, Yutian Li, Xiliang Li, Shuangmei Li, Ying-Bo Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Peilong Li, Kang Li, Yinghao Li, Lirong Li, Wenhong Li, Audrey Li, Yijian Li, Guang Y Li, Xianyong Li, Shilan Li, Guang-Li Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Guohua Li, Kezhen Li, Xingxing Li, Ellen Li, Yijie Li, Suwei Li, Shuyu D Li, Ruiwen Li, Jiandong Li, Fangyong Li, Binru Li, Yuchao Li, Hanlu Li, Jianang Li, Xue-Peng Li, Sheng-Tien Li, Shihao Li, Yazhou Li, Jun-Ling Li, Caesar Z Li, Lang Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Xinxiu Li, Chongyi Li, Yi-Ying Li, Shaodan Li, Yongzheng Li, Da-Hong Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Yaoyao Li, Yueguo Li, Mo Li, Ming-Hao Li, Hongsen Li, Menghua Li, Ka Li, Kaixin Li, Fuping Li, Jianbo Li, Xing-Wang Li, Chong Li, Fugen Li, Yuwei Li, Xiaochen Li, Zizhuo Li, Xiaoxiao Li, Le-Ying Li, Pengcui Li, Bing-Heng Li, Xiaoman Li, Xiaohong Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhifei Li, Jinhui Li, Yuanyou Li, Chongyang Li, Wanyan Li, Yumin Li, Longyu Li, X B Li, Jianguo Li, En Li, Ximei Li, Shaoyong Li, Kai-Wen Li, Guandu Li, Yixue Li, Junfeng Li, Xin-Chang Li, Yue-Ying Li, Kongdong Li, Lian Li, Xinmiao Li, Chenyang Li, Jiacheng Li, Xiaohua Li, Zhuangzhuang Li, Xiaohui Li, Cang Li, Xuepeng Li, Mingjiang Li, Zongyu Li, Shujie Li, Yanbin Li, Shiliang Li, Qinrui Li, Yiming Li, Xiao-Tong Li, Tie Li, Wei-Bo Li, Xiaoyi Li, Liyan Li, Xinke Li, Xiaokun Li, Ming-Wei Li, Minzhe Li, Wenfeng Li, Karen Li, X Li, Meifang Li, Yanjing Li, Maosheng Li, Ju-Rong Li, Shibo Li, Jin Li, Li-Na Li, Hui Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Vivian S W Li, Ranchang Li, Defu Li, Amy Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Zhu Li, Rongling Li, Tong-Ruei Li, Ben Li, Yingxia Li, Yonghe Li, Xinwei Li, Yu-I Li, Shunhua Li, Mingxi Li, Qionghua Li, Guo-Li Li, Xingchen Li, Tianjiao Li, Gui-Rong Li, Yunpeng Li, Qiong Li, Songyu Li, Shi-Fang Li, Shude Li, Zhibin Li, Yaxiong Li, Qing-Fang Li, Shengwen Li, Gui-Bo Li, Xueer Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Mingzhou Li, Taixu Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Meng Li, Cun Li, T Li, Yinghui Li, Feilong Li, Sin-Lun Li, Weiling Li, Mengfan Li, Jie Li, Shiyan Li, Lianbing Li, Yanchun Li, Xuze Li, Jialin Li, Wenjian Li, He Li, Bichun Li, Hanqin Li, Guoge Li, Wen-Wen Li, Keying Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Xiangrui Li, Caolong Li, Michelle Li, Chaojie Li, J Li, Zhi-Jian Li, Jianwei Li, Jiexin Li, Hongyan Li, Zhen-Xi Li, Guangdi Li, Xiaxia Li, Nien Li, Yuefeng Li, Peiyuan Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Fen Li, Jieshou Li, Roger Li, Mengqing Li, Menglu Li, Huiqing Li, Yantao Li, Ruolin Li, Yongle Li, Haying Li, Shao-Dan Li, Muzi Li, Gen Li, Dong-Ling Li, Chenwen Li, Le Li, Yong-Jian Li, Si-Wei Li, Manru Li, Yingxi Li, Caili Li, Yuqian Li, Wei-Dong Li, Guannan Li, Ya-Feng Li, Wenlong Li, Yuna Li, Shengli Li, Shugang Li, Xuan Li, Yongze Li, Yongxin Li, Lu Li, Zhuo-Rong Li, Qinglin Li, Bingbing Li, Runzhi Li, Qi-Jing Li, Zhenyan Li, Ji Xia Li, Yu-Ye Li, Meizi Li, Yuezheng Li, Zhengnan Li, Jianglong Li, Xiaozheng Li, Huili Li, Hongzhe K Li, Xiao-Qiu Li, Jiejia Li, Yi-Yang Li, Zhihui Li, Fujun Li, Ni Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Chunliang Li, Ruiyang Li, Chun Li, Jianan Li, Wenfang Li, Xiangling Li, Sung-Chou Li, Lianhong Li, Cheng Li, Tiegang Li, Zhong Li, Shuang-Ling Li, Xiao-Long Li, Xiaofei Li, Hung-Yuan Li, Zhang Li, Jianxin Li, H Li, Dongliang Li, Chenxiao Li, Hongjia Li, Xiao-Jing Li, Y H Li, Jian Li, Daoyuan Li, Baichuan Li, Zhenzhe Li, Jian-Mei Li, Kaimi Li, Peiran Li, Qiao Li, Yi-Yun Li, Xiao-Cheng Li, Yike Li, Yihan Li, Junsheng Li, Jiayu Li, Wen-Ya Li, Rongxia Li, Yunlun Li, Guoqin Li, Huiqin Li, Chunlin Li, Jisen Li, Peng Peng Li, Kenli Li, Guanglu Li, Xiushi Li, Dongmin Li, Jian-Jun Li, Fengyi Li, Yanling Li, Juanni Li, C Li, You-Mei Li, Beixu Li, Guiyuan Li, Suk-Yee Li, Shengjie Li, Yuanyuan Li, Xiaona Li, Shanyi Li, Chih-Chi Li, Hongbo Li, Xinhui Li, Jun Li, Mingzhe Li, Hongjuan Li, Senmao Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Yaying Li, Liqun Li, Changxian Li, Chunqing Li, Yanni Li, Yongsheng Li, Xiujuan Li, Huifang Li, Lingling Li, Xinhua Li, Minerva X Li, Alexander H Li, Wendeng Li, Ding Li, Ming-Yang Li, Shengze Li, Linyan Li, Hewei Li, Da-Jin Li, Xiao-kun Li, Yuanhao Li, Ji-Lin Li, Congcong Li, Juan Li, Xiaobin Li, Shaoqi Li, Yuehua Li, Jinfeng Li, Shiheng Li, Hsiao-Fen Li, Mengjiao Li, Tianxiang Li, Meng-Meng Li, Liangkui Li, Tian-chang Li, Yahui Li, Wenlei Li, Xi-Xi Li, Haiyan Li, Xujun Li, Chi-Ming Li, Yi-Ning Li, Dandan Li, Yunan Li, Sherly X Li, Jiazhou Li, Zhijun Li, Zechuan Li, Wanling Li, Zhiwei Li, Xueshan Li, Jiangbo Li, Xiaohan Li, Huijie Li, Zhongwen Li, W W Li, Yalan Li, Xuejun Li, Shunwang Li, Yaqing Li, Chao Li, Yaqiao Li, Bingsheng Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Haoran Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, Chumei Li, Shijie Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xiaochun Li, Rui Li, Xuemin Li, Shanpeng Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Xuyi Li, Yunchu Li, Zhengyao Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Lin-Feng Li, Ziqing Li, Shuangxiu Li, Yongjin Li, Chenhao Li, Weizu Li, Deming Li, Jiuyi Li, Chun-Xu Li, Luyao Li, Desheng Li, Long-Yan Li, Fuyu Li, Lingzhi Li, Xiao-Sa Li, Kunlin Li, Shu-Qi Li, Zehua Li, Mengyuan Li, Congye Li, Wensheng Li, Dehai Li, Qingshang Li, Jiannan Li, Guanbin Li, Zhiyi Li, Xing Li, Zhaoyong Li, SuYun Li, Shiyi Li, Suchun Li, Yanan Li, Jiayan Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, Dongdong Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Shaojing Li, S S Li, Tong Li, Yilong Li, Lihua Li, Xue-Lian Li, Yansen Li, Hai Li, Zhi-Yuan Li, Jingfeng Li, Yanli Li, Yuan-Jing Li, Kaibin Li, Xiaohu Li, Wenjie Li, Ruikai Li, Qiyong Li, Ruixi Li, Zhonglian Li, Dalin Li, Kun Li, Qizhai Li, Pengju Li, Peifeng Li, Ai-Jun Li, Yueting Li, YaJie Li, Zijian Li, Yanqing Li, Jixuan Li, Zhandong Li, Xuejie Li, Gaizhen Li, Liang Li, Huafang Li, Nianyu Li, Chenlu Li, X-L Li, Shawn S C Li, Cuiguang Li, Dongye Li, F Li, Chunhong Li, Yuan Li, Kunpeng Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Xinle Li, Wuguo Li, Bing-Hui Li, Honggang Li, Jingyong Li, Shikang Li, Shi-Ying Li, Ming Xing Li, Ming-Xing Li, Marilyn Li, Bei-Bei Li, Hong-Lian Li, Shishi Li, Haitong Li, Yuli Li, Ruibing Li, Qingfang Li, Qibing Li, Wende Li, Heng Li, Xiao-Na Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Baoting Li, Ka Wan Li, Huiyou Li, Binbin Li, Xinyao Li, Gui-xing Li, Niu Li, Shunle Li, Siyue Li, Diyan Li, Mengyao Li, Yixuan Li, Shan-Shan Li, Zhuanjian Li, Gerard Li, Yuyun Li, Zhiqiong Li, Zonglin Li, Pik Yi Li, Jingxin Li, Defeng Li, Zu-guo Li, Xin-Zhu Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Junhong Li, Youchen Li, W Y Li, Yi-Heng Li, Runbing Li, Yanmin Li, Jingyi Li, Yuxiang Li, Hao-Fei Li, Yining Li, Xiurong Li, Haiyu Li, Huijuan Li, Yunze Li, Xu-Zhao Li, Yanzhong Li, Kainan Li, Guohui Li, Xiaoyan Li, Xu-Bo Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Biao Li, Xiaoxuan Li, Anyao Li, Qing-Chang Li, Hongliang Li, Dalei Li, Zongjun Li, Changqing Li, Hanting Li, Dong-Jie Li, Xiaomin Li, Dengxiong Li, Yi-Shuan J Li, Tinghao Li, Zhouxiang Li, Yun-tian Li, Jianliang Li, Guangzhao Li, Yixi Li, Shuyu Dan Li, S A Li, Jinjie Li, Liming Li, Wenqun Li, Guixia Li, Yinan Li, Aoxi Li, Yuanjing Li, Linqi Li, Xixi Li, Bingjue Li, Binghu Li, Yu-Hang Li, Shuhui Li, Mengying Li, Yihong Li, Yaxian Li, Dali Li, Zhiming Li, Xuemei Li, Xueting Li, Yongting Li, Hongxia Li, Zhenjun Li, Danyang Li, Tiandong Li, Di-Jie Li, Bo Li, Jinliang Li, Qiji Li, Zhipeng Li, Xiaoping Li, Linhong Li, Taoyingnan Li, Lieyou Li, Huabin Li, Mao Li, Yongchao Li, Xiaoting Li, Ruotai Li, Yaojia Li, Xiao-Yao Li, Shangming Li, Yaqi Li, Yibo Li, Gui-Hua Li, Zhihong Li, Yandong Li, Chaowei Li, Huiyuan Li, Yuchun Li, Boya Li, Lamei Li, O Li, Joyce Li, Suheng Li, Hui-Ping Li, Junru Li, Zhiqiang Li, Jiangchao Li, Hecheng Li, Yueping Li, Changkai Li, Zhenglong Li, Yajuan Li, Chaoqian Li, Yu-Cheng Li, Yirun Li, Haomiao Li, Qianqian Li, YiQing Li, Zhengliang Li, Weijie Li, Wei-Qin Li, Zongyi Li, Qingxian Li, Dan-Dan Li, Yeshan Li, Zirui Li, Keke Li, Yongpeng Li, Chanyuan Li, Jianbin Li, Shiying Li, Zhongzhe Li, Yumei Li, Xiang-Ping Li, Wenqiang Li, Pei-Shan Li, Zaibo Li, Guangming Li, Xiaoqiang Li, Hanxiao Li, Jiansheng Li, Shuying Li, Xiaomei Li, Pengjie Li, Jiajia Li, Jingwen Li
articles
Liang Zhou, Guangyan Xu, Li Wang +2 more · 2021 · Disease markers · added 2026-04-24
An interaction between hypoxia and immunity has been confirmed in tumor tissue. However, there is no combined biomarker for diagnosis on this basis. Therefore, we developed a scoring formula based on Show more
An interaction between hypoxia and immunity has been confirmed in tumor tissue. However, there is no combined biomarker for diagnosis on this basis. Therefore, we developed a scoring formula based on markers of hypoxia and immunity. Firstly, the hypoxia-immune formula of lung adenocarcinoma (LUAD) was derived using LASSO-Cox regression in three cohorts from public database, and the corresponding score was calculated for each patient. The formula is as follows: combined hypoxia and immune index (CIHI) = LDHA expression × 0.2252 + GAPDH expression × 0.0727 + ANGPTL4 expression × 0.0724 + VEGFC expression × 0.1911 + DKK1 expression × 0.1355 + ADM expression × 0.0588 + BTK expression × -0.1659. Meanwhile, patients were divided into groups according to high and low CIHI, and expression profiles of hypoxia markers and immune markers were analyzed in different groups. CIHI was used to confirm that patients with high CIHI represented a state of hypoxia Show less
📄 PDF DOI: 10.1155/2021/4495489
ANGPTL4
Yuandong Cao, Aidi Gao, Xiaoqing Li +5 more · 2021 · Cancer medicine · Wiley · added 2026-04-24
Radiotherapy is one of the main strategies for the treatment of esophageal squamous cell carcinoma (ESCC). However, treatment failure often occurs due to the emergence of radioresistance. In this stud Show more
Radiotherapy is one of the main strategies for the treatment of esophageal squamous cell carcinoma (ESCC). However, treatment failure often occurs due to the emergence of radioresistance. In this study, we report a key regulator of radiation sensitivity, termed TAB182 that may become an ideal biomarker and therapeutic target to overcome radioresistance. By applying qRT-PCR and immunohistochemical staining, the expression of TAB182 was detected in patient tissues. We next assessed the influence of TAB182 downregulation to radiosensitivity using clonogenic survival assay and γ-H2A.X foci analysis in TE-1, TE-10, and radioresistant TE-1R cell lines after ionizing radiation. To unveil the mechanism underlying, TAB182 interacting proteins were identified by mass spectrometry following co-immunoprecipitation. Furthermore, flow cytometry and western blot assay were applied to validate the identified proteins. Our results demonstrated that the expression of TAB182 is higher in cancer tissues than normal tissues and elevated expression of TAB182 correlates with poor outcomes of postoperative radiotherapy. Downregulation of TAB182 sensitized cancer cells to ionizing radiation, particularly in radioresistant TE-1R cells that spontaneously overexpress TAB182. Mechanically, TAB182 interacts with FHL2 to induce G2-M arrest through wiring the CHK2/CDC25C/CDC2 signaling pathway. Finally, overexpression of shRNA-resistant TAB182 restored the checkpoint and radioresistance. TAB182 potentiates the radioresistance of ESCC cells by modulating the G2-M checkpoint through its interaction with FHL2. Thus, TAB182 may become an ideal biomarker and therapeutic target of ESCC radiotherapy. Show less
no PDF DOI: 10.1002/cam4.3879
TNKS1BP1
Tao Yang, Xian-Bo Zhang, Xiao-Na Li +2 more · 2021 · Neoplasma · added 2026-04-24
Homeobox C4 (HOXC4) belongs to the homeoprotein family of transcription factors, which play a critical role in morphogenesis and differentiation during embryonic development. Aberrant expression of HO Show more
Homeobox C4 (HOXC4) belongs to the homeoprotein family of transcription factors, which play a critical role in morphogenesis and differentiation during embryonic development. Aberrant expression of HOXC4 has been reported in several types of cancers. However, the role of HOXC4 in hepatocellular carcinoma (HCC) remains unknown. Here, we reported that HOXC4 is upregulated in HCC tissues and predicts a poor outcome in patients with HCC. HOXC4 promotes HCC progression and induces an EMT-like phenotype both in vitro and in vivo. Furthermore, we demonstrated that the EMT-related transcription factor Snail is a transcriptional target of HOXC4 and HOXC4 regulates EMT by regulation of transforming growth factor β (TGF-β) signaling in HCC. Together, our study suggests that HOXC4 as a novel potential therapeutic target for HCC therapy. Show less
no PDF DOI: 10.4149/neo_2020_200403N350
SNAI1
Xiaohong Meng, Yanling Long, Jiayun Ren +3 more · 2021 · Frontiers in cell and developmental biology · Frontiers · added 2026-04-24
Bardet-Biedl syndrome (BBS; OMIM 209900) is a rare genetic disease causing damage to multiple organs and affecting patients' quality of life in late adolescence or early adulthood. In this study, the Show more
Bardet-Biedl syndrome (BBS; OMIM 209900) is a rare genetic disease causing damage to multiple organs and affecting patients' quality of life in late adolescence or early adulthood. In this study, the ocular characteristics including morphology and function, were analyzed in 12 BBS patients from 10 Chinese families by molecular diagnostics. A total of five known and twelve novel variants in four Show less
📄 PDF DOI: 10.3389/fcell.2021.635216
BBS4

CD8

Kaiyi Zhang, Cong Tao, Jianping Xu +14 more · 2021 · Frontiers in immunology · Frontiers · added 2026-04-24
Anti-inflammatory therapies have the potential to become an effective treatment for obesity-related diseases. However, the huge gap of immune system between human and rodent leads to limitations of dr Show more
Anti-inflammatory therapies have the potential to become an effective treatment for obesity-related diseases. However, the huge gap of immune system between human and rodent leads to limitations of drug discovery. This work aims at constructing a transgenic pig model with higher risk of metabolic diseases and outlining the immune responses at the early stage of metaflammation by transcriptomic strategy. We used CRISPR/Cas9 techniques to targeted knock-in three humanized disease risk genes, Show less
📄 PDF DOI: 10.3389/fimmu.2021.690069
GIPR
Yuesheng Lv, Wenjing Zhang, Jinyao Zhao +13 more · 2021 · Signal transduction and targeted therapy · Nature · added 2026-04-24
Alternative splicing is a critical process to generate protein diversity. However, whether and how alternative splicing regulates autophagy remains largely elusive. Here we systematically identify the Show more
Alternative splicing is a critical process to generate protein diversity. However, whether and how alternative splicing regulates autophagy remains largely elusive. Here we systematically identify the splicing factor SRSF1 as an autophagy suppressor. Specifically, SRSF1 inhibits autophagosome formation by reducing the accumulation of LC3-II and numbers of autophagosomes in different cell lines. Mechanistically, SRSF1 promotes the splicing of the long isoform of Bcl-x that interacts with Beclin1, thereby dissociating the Beclin1-PIK3C3 complex. In addition, SRSF1 also directly interacts with PIK3C3 to disrupt the interaction between Beclin1 and PIK3C3. Consequently, the decrease of SRSF1 stabilizes the Beclin1 and PIK3C3 complex and activates autophagy. Interestingly, SRSF1 can be degraded by starvation- and oxidative stresses-induced autophagy through interacting with LC3-II, whereas reduced SRSF1 further promotes autophagy. This positive feedback is critical to inhibiting Gefitinib-resistant cancer cell progression both in vitro and in vivo. Consistently, the expression level of SRSF1 is inversely correlated to LC3 level in clinical cancer samples. Our study not only provides mechanistic insights of alternative splicing in autophagy regulation but also discovers a new regulatory role of SRSF1 in tumorigenesis, thereby offering a novel avenue for potential cancer therapeutics. Show less
no PDF DOI: 10.1038/s41392-021-00495-6
PIK3C3
Sha Wang, Anjie Yuan, Liping Zeng +5 more · 2021 · Journal of microbiology (Seoul, Korea) · Springer · added 2026-04-24
Aspergillus fumigatus is a well-known opportunistic pathogen that causes invasive aspergillosis (IA) infections with high mortality in immunosuppressed individuals. Morphogenesis, including hyphal gro Show more
Aspergillus fumigatus is a well-known opportunistic pathogen that causes invasive aspergillosis (IA) infections with high mortality in immunosuppressed individuals. Morphogenesis, including hyphal growth, conidiation, and cell wall biosynthesis is crucial in A. fumigatus pathogenesis. Based on a previous random insertional mutagenesis library, we identified the putative polysaccharide synthase gene Afcps1 and its para-log Afcps2. Homologs of the cps gene are commonly found in the genomes of most fungal and some bacterial pathogens. Afcps1/cpsA is important in sporulation, cell wall composition, and virulence. However, the precise regulation patterns of cell wall integrity by Afcps1/cpsA and further effects on the immune response are poorly understood. Specifically, our in-depth study revealed that Afcps1 affects cell-wall stability, showing an increased resistance of ΔAfcps1 to the chitinmicrofibril destabilizing compound calcofluor white (CFW) and susceptibility of ΔAfcps1 to the β-(1,3)-glucan synthase inhibitor echinocandin caspofungin (CS). Additionally, deletion of Afcps2 had a normal sporulation phenotype but caused hypersensitivity to Na Show less
no PDF DOI: 10.1007/s12275-021-0347-x
CPS1
Ming-Yue Wu, Le Liu, Er-Jin Wang +15 more · 2021 · Autophagy · Taylor & Francis · added 2026-04-24
NRBF2, a regulatory subunit of the ATG14-BECN1/Beclin 1-PIK3C3/VPS34 complex, positively regulates macroautophagy/autophagy. In this study, we report that NRBF2 is required for the clearance of apopto Show more
NRBF2, a regulatory subunit of the ATG14-BECN1/Beclin 1-PIK3C3/VPS34 complex, positively regulates macroautophagy/autophagy. In this study, we report that NRBF2 is required for the clearance of apoptotic cells and alleviation of inflammation during colitis in mice. NRBF2-deficient mice displayed much more severe colitis symptoms after the administration of ulcerative colitis inducer, dextran sulfate sodium salt (DSS), accompanied by prominent intestinal inflammation and apoptotic cell accumulation. Interestingly, we found that Show less
no PDF DOI: 10.1080/15548627.2020.1741332
PIK3C3
Liang Han, Zhe Chen, Kun Yu +12 more · 2021 · Frontiers in immunology · Frontiers · added 2026-04-24
The occurrence and development of rheumatoid arthritis (RA) is regulated by numerous cytokines. Interleukin 27 (IL-27) is a soluble cytokine that exerts biological effects by regulating the Janus tyro Show more
The occurrence and development of rheumatoid arthritis (RA) is regulated by numerous cytokines. Interleukin 27 (IL-27) is a soluble cytokine that exerts biological effects by regulating the Janus tyrosine kinase (JAK)/signal transducer and activator of the transcription (STAT) signaling pathway Show less
📄 PDF DOI: 10.3389/fimmu.2021.787252
IL27
Hong Yang, Hong Wang, Zongzhe Li +6 more · 2021 · Frontiers in cardiovascular medicine · Frontiers · added 2026-04-24
Coarctation of the aorta (CoA) is a common congenital cardiovascular malformation with aortic narrowing in the region of the ligamentum arteriosum. Hypertrophic cardiomyopathy (HCM) is a primary cardi Show more
Coarctation of the aorta (CoA) is a common congenital cardiovascular malformation with aortic narrowing in the region of the ligamentum arteriosum. Hypertrophic cardiomyopathy (HCM) is a primary cardiomyopathy that is characterized by left ventricular wall thickening and likely left ventricular outflow tract (LVOT) obstruction. They are two irrelevant diseases, and their coexistence has not been reported before. Here, we described a young female patient who concurrently has CoA and HCM. The patient has had hypertension since 18-years old and complained of chest discomfort on effort and fatigue thereafter. Initially, she was diagnosed as having hypertrophic cardiomyopathy and primary hypertension. The presence of CoA was not found until she was 35 years old when she had an onset of paroxysmal supraventricular tachycardia (PSVT) and presented with syncope. Failure of the ablation procedure Here, we reported the diagnostic challenges, management, and 8-yeasr follow-up findings in a rare case of CoA combined with HCM. The case highlighted the importance for physicians to exclude CoA in young hypertensive patients, and proved the efficacy of stent repair in treating CoA in older patients. Show less
no PDF DOI: 10.3389/fcvm.2021.818884
MYBPC3
Yingning Wu, Lingzhang Meng, Kai Cai +8 more · 2021 · Frontiers in oncology · Frontiers · added 2026-04-24
CD8+ T cells, which play a vital role in response to adaptive immunity, are closely related to the immunization responses to kill tumor cells. Understanding the effects exerted by tumor-infiltrated CD Show more
CD8+ T cells, which play a vital role in response to adaptive immunity, are closely related to the immunization responses to kill tumor cells. Understanding the effects exerted by tumor-infiltrated CD8+ T cells in HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) patients is critical for predicting their prognosis as well as their responses towards immunization-related therapy. HNSCC single cell transcriptome was used to screen for differentially expressed genes (DEGs) based on CD8+ T cells. A gene signature associated with CD8+ T cells was built and verified with the cancer genome atlas dataset with a view to predicting the prognosis of HNSCC patients. Risk scores were calculated for HNSCC cases and categorized into either high- or low-risk cohorts. The prognosis-correlated data of the risk scores were analyzed by using Kaplan-Meier survival curves and multi-variate Cox regression plots. In addition, the possibility of using the genetic profiles to predict responses toward immunization-related therapy was explored. From the DEGs screened from the sequencing of single-cell RNA, a gene signature of 4 genes (ACAP1, ANKRD28, C12orf75, and M6PR) were identified. It was seen that these genes could predict overall survival in HPV+ HNSCC patients. In addition, high- and low-risk HPV+ HNSCC patients showed marked differences in their CD8+ T-cell infiltration due to immunization when clinical characteristics were taken into consideration. This correlated with their immunization therapy responses. Our work provides insights into explaining the restricted responses of current immunization checkpoint inhibiting substances in HPV+ HNSCC patients. A novel genetic signature to predict the prognosis and immunization-correlated therapeutic responses is presented. This will provide potential new therapeutic opportunities for HPV+ HNSCC patients. Show less
📄 PDF DOI: 10.3389/fonc.2021.749398
ANKRD28
Shuai Huo, Hongxin Wang, Meixia Yan +12 more · 2021 · ACS omega · ACS Publications · added 2026-04-24
Hyperuricemia (HUA), a chronic disease caused by metabolic disorders of purine, is often accompanied by other diseases such as gout, type 2 diabetes mellitus (T2DM), and hyperlipidemia. However, littl Show more
Hyperuricemia (HUA), a chronic disease caused by metabolic disorders of purine, is often accompanied by other diseases such as gout, type 2 diabetes mellitus (T2DM), and hyperlipidemia. However, little is known about the relationship between HUA and these diseases on the protein level. We performed label-free liquid chromatography MS/MS spectrometry analysis of urine samples from 26 HUA patients and 25 healthy controls, attempting to establish the possible protein links between HUA and these diseases by profiling urine proteome. A total of 2119 proteins were characterized in sample proteomes. Among them, 11 were found decreased and 2 were found increased in HUA samples. Plausible pathways found by enrichment analysis of these differentially expressed proteins (DEPs) include the processes for insulin receptor recycling and lipid metabolism, suggesting potential links between HUA and T2DM and hyperlipidemia. The abundance changes of three key proteins (VATB1, CFAD, and APOC3) involved in these processes were validated by enzyme-linked immunosorbent assay (ELISA). In conclusion, our result provides proteomic evidence, for the first time, that the aberrant pathways enriched by described key DEPs are closely related to the incidence of HUA and its concomitant diseases. Show less
📄 PDF DOI: 10.1021/acsomega.0c06229
APOC3
Dandan Liu, Yanyan Han, Lei Liu +5 more · 2021 · International journal of oncology · added 2026-04-24
Parthenolide has been demonstrated to have anticancer effects against various types of cancer. However, the functional role of parthenolid has yet to be clearly reported in renal cell carcinoma (RCC). Show more
Parthenolide has been demonstrated to have anticancer effects against various types of cancer. However, the functional role of parthenolid has yet to be clearly reported in renal cell carcinoma (RCC). The aim of the present study was to investigate the effect of parthenolide in RCC 786‑O and ACHN cells. CCK‑8 and colony‑formation assays were used to observe the proliferation of RCC 786‑O and ACHN cells. Migration and invasion abilities were assessed through Transwell assays. The stem cell‑like properties of RCC cell lines were evaluated by mammosphere formation assay. Western blot analysis was used to investigate the metastasis and epithelial‑mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E‑cadherin, N‑cadherin, vimentin and snail. The results revealed that when the cells were treated with various concentrations of parthenolide, the rate of proliferation and growth was decreased in 786‑O and ACHN cells. The number of invasive cells in a field was approximately 170, 90, 40 and 190, 150, 70 in 786‑O and ACHN cells with 0, 4 and 8 µM of parthenolide treatment. MMP‑2/‑9 expression (P<0.05) was inhibited by parthenolide. The protein levels of E‑cadherin were increased (P<0.05) and N‑cadherin, vimentin and snail were decreased (P<0.05) by parthenolide treatment. In addition, Parthenolide inhibited the expression of cancer stem cell markers and the PI3K/AKT pathway. The present study confirmed that parthenolide inhibited RCC cell proliferation and metastasis and suppressed the stem cell‑like properties of RCC cell lines, which could be a potential strategy to treat RCC. However, further molecular mechanisms of parthenolide in RCC should be observed and reported in the future. Show less
no PDF DOI: 10.3892/ijo.2020.5148
SNAI1
Yohei Yoshihama, Kyle A LaBella, Eiru Kim +9 more · 2021 · Proceedings of the National Academy of Sciences of the United States of America · National Academy of Sciences · added 2026-04-24
Prostate cancer is a leading cause of cancer-related mortality in men. The widespread use of androgen receptor (AR) inhibitors has generated an increased incidence of AR-negative prostate cancer, trig Show more
Prostate cancer is a leading cause of cancer-related mortality in men. The widespread use of androgen receptor (AR) inhibitors has generated an increased incidence of AR-negative prostate cancer, triggering the need for effective therapies for such patients. Here, analysis of public genome-wide CRISPR screens in human prostate cancer cell lines identified histone demethylase JMJD1C (KDM3C) as an AR-negative context-specific vulnerability. Secondary validation studies in multiple cell lines and organoids, including isogenic models, confirmed that small hairpin RNA (shRNA)-mediated depletion of JMJD1C potently inhibited growth specifically in AR-negative prostate cancer cells. To explore the cooperative interactions of AR and JMJD1C, we performed comparative transcriptomics of 1) isogenic AR-positive versus AR-negative prostate cancer cells, 2) AR-positive versus AR-negative prostate cancer tumors, and 3) isogenic JMJD1C-expressing versus JMJD1C-depleted AR-negative prostate cancer cells. Loss of AR or JMJD1C generates a modest tumor necrosis factor alpha (TNFα) signature, whereas combined loss of AR and JMJD1C strongly up-regulates the TNFα signature in human prostate cancer, suggesting TNFα signaling as a point of convergence for the combined actions of AR and JMJD1C. Correspondingly, AR-negative prostate cancer cells showed exquisite sensitivity to TNFα treatment and, conversely, TNFα pathway inhibition via inhibition of its downstream effector MAP4K4 partially reversed the growth defect of JMJD1C-depleted AR-negative prostate cancer cells. Given the deleterious systemic side effects of TNFα therapy in humans and the viability of JMJD1C-knockout mice, the identification of JMJD1C inhibition as a specific vulnerability in AR-negative prostate cancer may provide an alternative drug target for prostate cancer patients progressing on AR inhibitor therapy. Show less
no PDF DOI: 10.1073/pnas.2026324118
JMJD1C
Xiang Jiang, Ganggang Wang, Yingyi Liu +8 more · 2021 · Cancer letters · Elsevier · added 2026-04-24
Hepatocellular carcinoma (HCC) is a malignancy found at high frequency around the world. Unfortunately, the scarcity of effective early diagnostic methods invariably results in poor outcomes. Long non Show more
Hepatocellular carcinoma (HCC) is a malignancy found at high frequency around the world. Unfortunately, the scarcity of effective early diagnostic methods invariably results in poor outcomes. Long noncoding RNAs (lncRNAs) are known to regulate the progression of hepatocellular carcinoma (HCC). A novel lncRNA RP11-286H15.1(OTTHUMG00000186042) has been identified and associated with HCC; however, the potential role of RP11-286H15.1 in HCC remains undefined. The transcript abundance of RP11-286H15.1 in 80 pairs of HCC samples and cell lines was evaluated by qRT-PCR analysis. The functional role of RP11-286H15.1 in HCC was tested in vivo and in vitro. The mechanisms underlying the role of RP11-286H15.1 in HCC were explored by RNA pulldown, transcriptome sequencing, and RNA immunoprecipitation (RIP), ubiquitination and fluorescence in situ hybridization (FISH) assays as well as Western blot analysis. The qRT-PCR and FISH assays revealed that RP11-286H15.1 was significantly decreased in HCC, and implied a shorter survival time. RP11-286H15.1 overexpression inhibited HCC cell proliferation and metastasis in vitro and in vivo, whereas RP11-286H15.1 knockdown produced the opposite results. Furthermore, we confirmed that RP11-286H15.1 (620-750 nucleotides) binds to poly(A) binding protein 4 (PABPC4) and promotes its ubiquitination, thus, reducing the stability of TRIM37 and CDC27 mRNAs. Our study demonstrates that a novel lncRNA, RP11-286H15.1, represses HCC progression by promoting PABPC4 ubiquitination. These findings highlight potential therapeutic targets for HCC. Show less
no PDF DOI: 10.1016/j.canlet.2020.11.038
PABPC4
Siyuan Gan, Ruifang Ye, Yanping Ha +6 more · 2021 · Combinatorial chemistry & high throughput screening · Bentham Science · added 2026-04-24
Prediction biomarkers associated with prognosis and lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) are needed to facilitate clinicians in choosing appropriate therapies. We hope to i Show more
Prediction biomarkers associated with prognosis and lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) are needed to facilitate clinicians in choosing appropriate therapies. We hope to identify key genes associated with LNM and prognosis in PTC. GSE29265, GSE33630, GSE3467, GSE3678 and GSE58545 gene expression profiles were acquired from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) between PTC tissues and normal thyroid tissues were selected with the GEO2R tool, and common DEGs among the five datasets were integrated with Venn software online. A proteinprotein interaction (PPI) network of the common DEGs was visualized. We analyzed the PPI network and determined core genes using the Cytoscape software. Furthermore, we employed UALCAN to verify the expression and promoter methylation status of the core genes in thyroid carcinoma (THCA). Additionally, the Kaplan-Meier plotter online tool was used to analyze the relationship between overall survival and core gene expressions in THCA. TNS3, DUSP6, DUSP4 and PTPRE were identified as core genes. Expression of these 4 genes and the promoter methylation status of DUSP4 and PTPRE were strongly associated with LNM (P<0.05). High expression of 3 genes (DUSP6, DUSP4 and PTPRE) was related to a significantly better survival than low expression of the 3 genes in THCA. In contrast, high TNS3 expression was related to significantly worse survival (P<0.05). TNS3, DUSP6, DUSP4, PTPRE and DUSP4 and PTPRE promoter methylation status might be useful predictive biomarkers of LNM in PTC. Additionally, these genes may be prognostic biomarkers in PTC. Show less
no PDF DOI: 10.2174/1386207323999201103205745
DUSP6
Dai Zhang, Yiche Li, Si Yang +10 more · 2021 · Cancer medicine · Wiley · added 2026-04-24
Ovarian cancer (OV) is deemed the most lethal gynecological cancer in women. The aim of this study was to construct an effective gene prognostic model for predicting overall survival (OS) in patients Show more
Ovarian cancer (OV) is deemed the most lethal gynecological cancer in women. The aim of this study was to construct an effective gene prognostic model for predicting overall survival (OS) in patients with OV. The expression profiles of glycolysis-related genes (GRGs) and clinical data of patients with OV were extracted from The Cancer Genome Atlas (TCGA) database. Univariate, multivariate, and least absolute shrinkage and selection operator Cox regression analyses were conducted, and a prognostic signature based on GRGs was constructed. The predictive ability of the signature was analyzed using training and test sets. A gene risk signature based on nine GRGs (ISG20, CITED2, PYGB, IRS2, ANGPTL4, TGFBI, LHX9, PC, and DDIT4) was identified to predict the survival outcome of patients with OV. The signature showed a good prognostic ability for OV, particularly high-grade OV, in the TCGA dataset, with areas under the curve (AUC) of 0.709 and 0.762 for 3- and 5-year survival, respectively. Similar results were found in the test sets, and the AUCs of 3-, 5-year OS were 0.714 and 0.772 in the combined test set. And our signature was an independent prognostic factor. Moreover, a nomogram combining the prediction model and clinical factors was developed. Our study established a nine-GRG risk model and nomogram to better predict OS in patients with OV. The risk model represents a promising and independent prognostic predictor for patients with OV. Moreover, our study on GRGs could offer guidance for the elucidation of underlying mechanisms in future studies. Show less
📄 PDF DOI: 10.1002/cam4.4317
ANGPTL4
Zhongping Ning, Xinming Li, Xi Zhu +2 more · 2021 · The Journal of international medical research · SAGE Publications · added 2026-04-24
To investigate the association between serum angiopoietin-like 4 (ANGPTL4) levels and recurrence of atrial fibrillation (AF) after catheter ablation. This retrospective study recruited patients with A Show more
To investigate the association between serum angiopoietin-like 4 (ANGPTL4) levels and recurrence of atrial fibrillation (AF) after catheter ablation. This retrospective study recruited patients with AF undergoing catheter ablation and they were divided into two groups (new-onset AF group and recurrent AF group). Demographic, clinical, and laboratory parameters were collected. A total of 192 patients with AF were included, including 69 patients with recurrence of AF. Serum ANGPTL4 levels were lower in patients with recurrent AF than in those with new-onset AF. Serum ANGPTL4 levels were positively correlated with superoxide dismutase and peroxisome proliferator-activated receptor γ, and negatively correlated with the CHA2DS2-VASC score, left atrial diameter, and levels of brain natriuretic peptide, malondialdehyde, high-sensitivity C-reactive protein, and interleukin-6. The receiver operating characteristic curve showed that the best cut-off for recurrent AF was serum ANGPTL4 levels  < 19.735 ng/mL, with a sensitivity and specificity of 63.9% and 74.5%, respectively. Serum ANGPTL4 levels were significantly associated with recurrence and new onset of AF (odds ratio, 2.241; 95% confidence interval, 1.081-4.648). Serum ANGPTL4 levels are lower in patients with recurrent AF than in those with new-onset AF, and are associated with cardiac hypertrophy, oxidative stress, and inflammation. Show less
📄 PDF DOI: 10.1177/0300060520988393
ANGPTL4
Xiao-Lan Wang, Lianjian Li · 2021 · BMC neurology · BioMed Central · added 2026-04-24
Alzheimer's disease (AD) is a pervasive age-related and highly heritable neurodegenerative disorder but has no effective therapy. The complex cellular microenvironment in the AD brain impedes our unde Show more
Alzheimer's disease (AD) is a pervasive age-related and highly heritable neurodegenerative disorder but has no effective therapy. The complex cellular microenvironment in the AD brain impedes our understanding of pathogenesis. Thus, a comprehensive investigation of cell type-specific responses in AD is crucial to provide precise molecular and cellular targets for therapeutic development. Here, we integrated analyzed 4,441 differentially expressed genes (DEGs) that were identified from 263,370 single-cells in cortex samples by single-nucleus RNA sequencing (snRNA-seq) between 42 AD-pathology subjects and 39 normal controls within 3 studies. DEGs were analyzed in microglia, astrocytes, oligodendrocytes, excitatory neurons, inhibitory neurons, and endothelial cells, respectively. In each cell type, we identified both common DEGs which were observed in all 3 studies, and overlapping DEGs which have been seen in at least 2 studies. Firstly, we showed the common DEGs expression and explained the biological functions by comparing with existing literature or multil-omics signaling pathways knowledgebase. We then determined the significant modules and hub genes, and explored the biological processes using the overlapping DEGs. Finally, we identified the common and distinct dysregulated pathways using overall DEGs and overlapping DEGs in a cell type-specific manner. Up-regulated LINGO1 has been seen in both oligodendrocytes and excitatory neurons across 3 studies. Interestingly, genes enriched in the mitochondrial module were up-regulated across all cell types, which indicates mitochondrial dysfunction in the AD brain. The estrogen signaling pathway seems to be the most common pathway that is disrupted in AD. Together, these analyses provide detailed information of cell type-specific and overall transcriptional changes and pathways underlying the human AD-pathology. These findings may provide important insights for drug development to tackle this disease. Show less
📄 PDF DOI: 10.1186/s12883-021-02407-1
LINGO1
Chunyan Wei, Xiaoqing Liu, Qin Wang +2 more · 2021 · International journal of endocrinology · added 2026-04-24
The 5-year overall survival rate of ovarian cancer (OC) patients is less than 40%. Hypoxia promotes the proliferation of OC cells and leads to the decline of cell immunity. It is crucial to find poten Show more
The 5-year overall survival rate of ovarian cancer (OC) patients is less than 40%. Hypoxia promotes the proliferation of OC cells and leads to the decline of cell immunity. It is crucial to find potential predictors or risk model related to OC prognosis. This study aimed at establishing the hypoxia-associated gene signature to assess tumor immune microenvironment and predicting the prognosis of OC. The gene expression data of 378 OC patients and 370 OC patients were downloaded from datasets. The hypoxia risk model was constructed to reflect the immune microenvironment in OC and predict prognosis. 8 genes (AKAP12, ALDOC, ANGPTL4, CITED2, ISG20, PPP1R15A, PRDX5, and TGFBI) were included in the hypoxic gene signature. Patients in the high hypoxia risk group showed worse survival. Hypoxia signature significantly related to clinical features and may serve as an independent prognostic factor for OC patients. 2 types of immune cells, plasmacytoid dendritic cell and regulatory T cell, showed a significant infiltration in the tissues of the high hypoxia risk group patients. Most of the immunosuppressive genes (such as ARG1, CD160, CD244, CXCL12, DNMT1, and HAVCR1) and immune checkpoints (such as CD80, CTLA4, and CD274) were upregulated in the high hypoxia risk group. Gene sets related to the high hypoxia risk group were associated with signaling pathways of cell cycle, MAPK, mTOR, PI3K-Akt, VEGF, and AMPK. The hypoxia risk model could serve as an independent prognostic indicator and reflect overall immune response intensity in the OC microenvironment. Show less
📄 PDF DOI: 10.1155/2021/4156187
ANGPTL4
Jie Li, Ming-Han Li, Tian-Tian Wang +10 more · 2021 · British journal of cancer · Nature · added 2026-04-24
Many molecular alterations are shared by embryonic liver development and hepatocellular carcinoma (HCC). Identifying the common molecular events would provide a novel prognostic biomarker and therapeu Show more
Many molecular alterations are shared by embryonic liver development and hepatocellular carcinoma (HCC). Identifying the common molecular events would provide a novel prognostic biomarker and therapeutic target for HCC. Expression levels and clinical relevancies of SLC38A4 and HMGCS2 were investigated by qRT-PCR, western blot, TCGA and GEO datasets. The biological roles of SLC38A4 were investigated by functional assays. The downstream signalling pathway of SLC38A4 was investigated by qRT-PCR, western blot, immunofluorescence, luciferase reporter assay, TCGA and GEO datasets. SLC38A4 silencing was identified as an oncofetal molecular event. DNA hypermethylation contributed to the downregulations of Slc38a4/SLC38A4 in the foetal liver and HCC. Low expression of SLC38A4 was associated with poor prognosis of HCC patients. Functional assays demonstrated that SLC38A4 depletion promoted HCC cellular proliferation, stemness and migration, and inhibited HCC cellular apoptosis in vitro, and further repressed HCC tumorigenesis in vivo. HMGCS2 was identified as a critical downstream target of SLC38A4. SLC38A4 increased HMGCS2 expression via upregulating AXIN1 and repressing Wnt/β-catenin/MYC axis. Functional rescue assays showed that HMGCS2 overexpression reversed the oncogenic roles of SLC38A4 depletion in HCC. SLC38A4 downregulation was identified as a novel oncofetal event, and SLC38A4 was identified as a novel tumour suppressor in HCC. Show less
no PDF DOI: 10.1038/s41416-021-01490-y
AXIN1
Lichun Xiao, Yu Bei, Jian'an Li +3 more · 2021 · Chemical & pharmaceutical bulletin · added 2026-04-24
17β Hydroxysteroid dehydrogenase type 3 (17β-HSD3) is the key enzyme in the biosynthesis of testosterone, which is an attractive therapeutic target for prostate cancer (PCa). H10, a novel curcumin ana Show more
17β Hydroxysteroid dehydrogenase type 3 (17β-HSD3) is the key enzyme in the biosynthesis of testosterone, which is an attractive therapeutic target for prostate cancer (PCa). H10, a novel curcumin analogue, was identified as a potential 17β-HSD3 inhibitor. The pharmacokinetic study of H10 in rats were performed by intraperitoneal (i.p.), intravenous (i.v.) and oral (p.o.) administration. In addition, the inhibitory effects of H10 against liver CYP3A4 were investigated in vitro using human liver microsomes (HLMs). The acute and chronic toxicological characteristics were characterized using single-dose and 30 d administration. All the mice were alive after i.p. H10 with dose of no more than 100 mg/kg which are nearly the maximum solubility in acute toxicity test. The pharmacokinetic characteristics of H10 fitted with linear dynamics model after single dose. Furthermore, H10 could bioaccumulate in testis, which was the target organ of 17β-HSD3 inhibitor. H10 distributed highest in spleen, and then in liver both after single and multiple i.p. administration. Moreover, H10 showed weak inhibition towards liver CYP3A4, and did not cause significant changes in aspartate transaminase (AST) and alanine transaminase (ALT) levels after treated with H10 for continuously 30 d. Taken together, these preclinical characteristics laid the foundation for further clinical studies of H10. Show less
no PDF DOI: 10.1248/cpb.c20-00242
HSD17B12
Jie Yan, Wu-Jun Li, Ya-Zhou Qin +3 more · 2021 · International journal of ophthalmology · added 2026-04-24
To quantitatively detect aqueous levels of angiopoietin-like (ANGPTL)3, ANGPTL4, and ANGPTL6 and investigate their correlation with optical coherence tomography angiography (OCTA) findings in patients Show more
To quantitatively detect aqueous levels of angiopoietin-like (ANGPTL)3, ANGPTL4, and ANGPTL6 and investigate their correlation with optical coherence tomography angiography (OCTA) findings in patients with diabetic macular edema (DME). This cross-sectional study included 23 patients (27 eyes) with type 2 diabetes and 16 control subjects (20 eyes). All patients underwent OCTA imaging and ultra-wide field fundus photography. Diabetic patients were categorized into two groups according to the presence or absence of diabetic retinopathy (DME group, 14 patients, 16 eyes); and non-diabetic retinopathy (NDR) group, 9 patients, 11 eyes, respectively. Aqueous levels of ANGPTL3, ANGPTL4, and ANGPTL6 were assessed using suspension array technology, and foveal-centered 3×3 mm Aqueous ANGPTL3 levels were not significantly different among the three groups ( ANGPTL4 and ANGPTL6 may be associated with vascular leakage in DME and may represent good targets for DME therapy. In addition, OCTA metrics may be useful for evaluating macular ischemia in DME. Show less
no PDF DOI: 10.18240/ijo.2021.12.12
ANGPTL4
Ran Li, Chen Hu, Jianning Wang +4 more · 2021 · Microorganisms · MDPI · added 2026-04-24
Marine protists are essential for globally critical biological processes, including the biogeochemical cycles of matter and energy. However, compared with their prokaryotic counterpart, it remains lar Show more
Marine protists are essential for globally critical biological processes, including the biogeochemical cycles of matter and energy. However, compared with their prokaryotic counterpart, it remains largely unclear how environmental factors determine the diversity and distribution of the active protistan communities on the regional scale. In the present study, the biodiversity, community composition, and potential drivers of the total, abundant, and rare protistan groups were studied using high throughput sequencing on the V9 hyper-variable regions of the small subunit ribosomal RNA (SSU rRNA) along an estuary to basin transect in the northern South China Sea. Overall, Bacillariophyta and Cercozoa were abundant in the surface water; heterotrophic protists including Spirotrichea and marine stramenopiles 3 (MAST-3) were more abundant in the subsurface waters near the heavily urbanized Pearl River estuary; Chlorophyta and Pelagophyceae were abundant at the deep chlorophyll maximum depth, while Hacrobia, Radiolaria, and Excavata were the abundant groups in the deep water. Salinity, followed by water depth, temperature, and other biological factors, were the primary factors controlling the distinct vertical and horizontal distribution of the total and abundant protists. Rare taxa were driven by water depth, followed by temperature, salinity, and the concentrations of PO Show less
📄 PDF DOI: 10.3390/microorganisms9020351
MAST3
Nuan Song, Xiaojing Li, Yuan Cui +3 more · 2021 · Journal of hazardous materials · Elsevier · added 2026-04-24
Hydrogen sulfide (H
no PDF DOI: 10.1016/j.jhazmat.2021.126172
DUSP6
Binglan Li, Yogasudha Veturi, Anurag Verma +8 more · 2021 · PLoS genetics · PLOS · added 2026-04-24
As a type of relatively new methodology, the transcriptome-wide association study (TWAS) has gained interest due to capacity for gene-level association testing. However, the development of TWAS has ou Show more
As a type of relatively new methodology, the transcriptome-wide association study (TWAS) has gained interest due to capacity for gene-level association testing. However, the development of TWAS has outpaced statistical evaluation of TWAS gene prioritization performance. Current TWAS methods vary in underlying biological assumptions about tissue specificity of transcriptional regulatory mechanisms. In a previous study from our group, this may have affected whether TWAS methods better identified associations in single tissues versus multiple tissues. We therefore designed simulation analyses to examine how the interplay between particular TWAS methods and tissue specificity of gene expression affects power and type I error rates for gene prioritization. We found that cross-tissue identification of expression quantitative trait loci (eQTLs) improved TWAS power. Single-tissue TWAS (i.e., PrediXcan) had robust power to identify genes expressed in single tissues, but, often found significant associations in the wrong tissues as well (therefore had high false positive rates). Cross-tissue TWAS (i.e., UTMOST) had overall equal or greater power and controlled type I error rates for genes expressed in multiple tissues. Based on these simulation results, we applied a tissue specificity-aware TWAS (TSA-TWAS) analytic framework to look for gene-based associations with pre-treatment laboratory values from AIDS Clinical Trial Group (ACTG) studies. We replicated several proof-of-concept transcriptionally regulated gene-trait associations, including UGT1A1 (encoding bilirubin uridine diphosphate glucuronosyltransferase enzyme) and total bilirubin levels (p = 3.59×10-12), and CETP (cholesteryl ester transfer protein) with high-density lipoprotein cholesterol (p = 4.49×10-12). We also identified several novel genes associated with metabolic and virologic traits, as well as pleiotropic genes that linked plasma viral load, absolute basophil count, and/or triglyceride levels. By highlighting the advantages of different TWAS methods, our simulation study promotes a tissue specificity-aware TWAS analytic framework that revealed novel aspects of HIV-related traits. Show less
📄 PDF DOI: 10.1371/journal.pgen.1009464
CETP
Chunhua Chen, Shiheng Li, Junli Xue +6 more · 2021 · JCI insight · added 2026-04-24
Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less appreciated in tumor biolo Show more
Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less appreciated in tumor biology and therapeutics development, partly because of the incomplete mechanistic understanding. Here we demonstrate a potentially novel mechanism by which PD-L1 promotes the epithelial-mesenchymal transition (EMT) in triple-negative breast cancer (TNBC) cells by suppressing the destruction of the EMT transcription factor Snail. PD-L1 directly binds to and inhibits the tyrosine phosphatase PTP1B, thus preserving p38-MAPK activity that phosphorylates and inhibits glycogen synthase kinase 3β (GSK3β). Via this mechanism, PD-L1 prevents the GSK3β-mediated phosphorylation, ubiquitination, and degradation of Snail and consequently promotes the EMT and metastatic potential of TNBC. Significantly, PD-L1 antibodies that confine the tumor-intrinsic PD-L1/Snail pathway restricted TNBC progression in immunodeficient mice. More importantly, targeting both tumor-intrinsic and tumor-extrinsic functions of PD-L1 showed strong synergistic tumor suppression effect in an immunocompetent TNBC mouse model. Our findings support that PD-L1 intrinsically facilitates TNBC progression by promoting the EMT, and this potentially novel PD-L1 signaling pathway could be targeted for better clinical management of PD-L1-overexpressing TNBCs. Show less
no PDF DOI: 10.1172/jci.insight.131458
SNAI1
Zhihua Ye, Junkai Zhang, Yingyu Yang +3 more · 2021 · Journal of B.U.ON. : official journal of the Balkan Union of Oncology · added 2026-04-24
To investigate whether RBM6 can serve as a suppressor gene in hepatocellular carcinoma (HCC) and affect its progression. QPCR and Western blot were carried out to measure RBM6 expression in tissue sam Show more
To investigate whether RBM6 can serve as a suppressor gene in hepatocellular carcinoma (HCC) and affect its progression. QPCR and Western blot were carried out to measure RBM6 expression in tissue samples collected from HCC patients with different tumor sizes or in different stages. The relationship between overall survival (OS) and RBM6 expression in patients with HCC was analyzed using Kaplan-Meier survival method. Meanwhile, the effects of different factors on HCC progression were evaluated through Cox regression analysis. After over-expression of RBM6 in HepG2 and HB611 cells, the cell viability, cell migration and invasion abilities and apoptosis rate were assessed by cell counting kit-8 (CCK-8), transwell assay, and flow cytometry analysis, respectively. RBM6 expression, markedly down-regulated in HCC tissues, showed a great relevance to tumor size, TNM stage, and histological grade, and the survival rate of patients in high RBM6 expression group was higher than those in low RBM6 expression group. Besides, Cox regression analysis revealed that RBM6 expression, tumor size, TNM stage and histological grade were four independent factors affecting the OS of HCC patients. Moreover, in vitro cell experiments demonstrated that overexpression of RBM6 significantly attenuated the cell viability as well as the invasive ability while enhanced cell apoptosis. The low expression of RBM6 contributes to the improvement of the survival of patients with HCC. Therefore, RBM6 can serve as a tumor-suppressing gene to repress cell proliferation, migration and invasion and promote cell apoptosis, thereby affecting the progression of HCC. Show less
no PDF
RBM6
Guifang Gan, Zhaopeng Shi, Chengfang Shangguan +8 more · 2021 · Theranostics · added 2026-04-24
📄 PDF DOI: 10.7150/thno.59841
DUSP6
Deqiang Li, Junlong Zhang, Lijun Yin +3 more · 2021 · Experimental and therapeutic medicine · added 2026-04-24
Etomidate (ETO) is a commonly used intravenous anesthetic that has been reported to exert a tumor suppressive effect in several types of cancer. The present study aimed to investigate the effect of ET Show more
Etomidate (ETO) is a commonly used intravenous anesthetic that has been reported to exert a tumor suppressive effect in several types of cancer. The present study aimed to investigate the effect of ETO on cell proliferation and apoptosis in non-small cell lung cancer (NSCLC) cells and elucidate its potential mechanism of action. Therefore, Cell Counting Kit-8 assay was performed to evaluate the effect of different concentrations of ETO (0, 1, 2 or 3 µg/ml) on A549 cell viability. In addition, the possible interaction between ETO and WW domain containing E3 ubiquitin protein ligase 2 (WWP2) was predicted using the STITCH database. Additionally, a stable WWP2-overexpressing A549 cell line was constructed by transfecting A549 cells with the pcDNA3.1-WWP2 plasmid. Cell proliferation and apoptosis were assessed using colony formation and TUNEL assays, respectively. The mRNA and protein expression levels of the apoptosis-related proteins Bcl-2, Bax, caspase 3 and cleaved-caspase 3 were determined by reverse transcription-quantitative PCR and western blotting. In addition, the expression and phosphorylation levels of proliferation-associated genes (PCNA and Ki-67) and proteins in the PI3K/Akt pathway were analyzed by western blotting. The results showed that treatment with ETO attenuated the cell viability and proliferation of A549 cells. ETO also promoted cell apoptosis and decreased the expression of the anti-apoptotic protein Bcl-2, whilst increasing that of pro-apoptotic proteins Bax and cleaved caspase 3 in a dose-dependent manner. Furthermore, ETO was found to negatively regulate the expression of WWP2, such that WWP2 overexpression reversed the potentiating effects of ETO on cell apoptosis. In addition, ETO promoted the expression of PTEN and reduced the phosphorylation levels of the PI3K/AKT pathway-related proteins. These effects aforementioned could also be reversed by WWP2 overexpression. Therefore, data from the present study suggest that ETO can attenuate the progression of NSCLC through by the PI3K/AKT pathway, specifically by targeting WWP2. These findings may provide a novel target for the treatment of NSCLC. Show less
no PDF DOI: 10.3892/etm.2021.10689
WWP2